As lorlatinib is effective against central nervous system metastasis even in patients pretreated with first- and second-generation ALK-TKIs [10], the known capacity of silibinin to provide better control of brain disease and allow a higher proportion of patients with NSCLC to receive additional lines of treatment [53,54] could be exploited by utilizing its ability to ameliorate lorlatinib-induced hyperlipidemia. The gene discussed is ALK; the disease is non-small cell lung carcinoma.